Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Krischer, Jeffrey P.; Epstein, Stacy; Cuthbertson, David; Goorin, Allen M.; Epstein, M. A.; Lipshultz, Steven E.

doi:10.1200/jco.1997.15.4.1544

Cited by 441 publications

(349 citation statements)

References 44 publications

Supporting

Mentioning

319

Contrasting

Unclassified

Order By: Relevance

“…Because the chemotherapy she received prior to BMT consisted of a high cumulative dose of doxorubicin, she was put at high risk of anthracycline-associated cardiotoxicity, which can lead to a decline in left ventricular function. 7 Up to 65% of childhood survivors treated with anthracyclines demonstrate abnormalities in left ventricular contraction, which can progress to congestive heart failure. 8,9 The Children's Oncology Group (COG) recommends baseline echocardiograms and electrocardiograms with QTc interval evaluations prior to anthracycline exposure and at certain milestones.…”

Section: Introductionmentioning

confidence: 99%

Childhood to adult transition and long-term follow-up after blood and marrow transplantation

Cupit

Duncan

Savani

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a host of long-term side effects and complications. The pediatric and adolescent and young adult (AYA) populations comprise an increasing proportion of BMT survivors. Though these populations are both at risk of a specific set of sequelae and faced with the additional challenge of transitioning to adult care, no previous literature has addressed their specific challenges. In this review, we illustrate with clinical vignettes the need for focused and specific survivorship clinics for pediatric/AYA BMT survivors. We then focus on the following areas pertaining to pediatric BMT survivorship and care: (1) psychological health, (2) neurocognition, (3) endocrine health, (4) infertility resources, (5) issues in transition from pediatric to adult clinicians, (6) preventative services and (7) cost of care issues.

show abstract

Section: Introductionmentioning

confidence: 99%

Childhood to adult transition and long-term follow-up after blood and marrow transplantation

Cupit

Duncan

Savani

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…8 Among the main limitations to the use of high-dose DNR are its acute and chronic cardiotoxicity. 9,10 To overcome or reduce this problem, the new anthracycline idarubicin (IDA) has been proposed as a therapeutic option to the use of DNR. In an early Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) pilot study, we achieved 82% CR in a small number of APL patients using IDA as a singleinduction chemotherapeutic agent; no cardiac toxicity was observed among the treated patients.…”

Section: Introductionmentioning

confidence: 99%

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Avvisati

Petti

Lo‐Coco

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

“…21 Cardiovascular complications may impair childhood cancer survivors' perceived physical health. 12,22,23 We examined self-reported general health, vitality, and physical function and self-reported cardiac symptoms that corresponded to the New York Heart Association (NYHA) cardiac classification in childhood cancer survivors; we compared those findings with the results from noninvasive assessment of cardiac systolic function, cancer treatment history, and self-reported cardiac risk factors.…”

mentioning

confidence: 99%

Subclinical late cardiac toxicity in childhood cancer survivors

Cox

Shesh

Rosenthal

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe authors analyzed how self‐reported health and self‐reported modified New York Heart Association (NYHA) cardiac function scores were related to cardiac systolic function, cardiac risk factors, and cancer treatment history in childhood cancer survivors who reported no symptoms of cardiac disease.METHODSLong‐term survivors of pediatric cancer who were treated between 1971 and 1995 (current ages, 16–39.7 years) underwent noninvasive clinical and laboratory cardiac risk evaluation and responded to selected subscales of the Medical Outcomes Study 36‐item Short Form Health Survey. Results were compared with survivor history of anthracycline therapy alone or with radiotherapy (n = 127 patients; mean, 10 years after diagnosis) versus no anthracycline therapy (n = 32 patients; mean, 11 years after diagnosis).RESULTSSex, current age, highest school grade completed, race, age at diagnosis, diagnostic group, years off therapy, fractional shortening (FS), heart rate, and smoking status were found to be independently predictive of self‐reported health. Interaction between female sex and higher low‐density lipoprotein values and between diagnosis and abnormal FS variably predicted low reported vitality and low reported modified New York Heart Association (NYHA) scores. Echocardiographic findings, cardiac risk factors, and treatment history explained 13% to 28% of the variance in perceived health and self‐reported modified NYHA scores.CONCLUSIONSSystolic function and cardiac risk factors were linked to lower self‐reported health and NYHA scores even in the absence of clinically evident cardiotoxicity. Cancer 2008. ©2008 American Cancer Society.

show abstract

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Abstract: Early clinical cardiotoxicity in children treated with anthracycline is rare. A high maximal dose, or cumulative dose of anthracycline, female sex, black race, presence of trisomy 21, and treatment with amsacrine increase the risk for anthracycline-associated cardiotoxicity.

Cited by 441 publications

References 44 publications

Childhood to adult transition and long-term follow-up after blood and marrow transplantation

Childhood to adult transition and long-term follow-up after blood and marrow transplantation

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Subclinical late cardiac toxicity in childhood cancer survivors

Contact Info

Product

Resources

About